U.S. markets open in 4 hours 38 minutes

bioMérieux S.A. (BIM.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
98.62-0.82 (-0.82%)
As of 10:37AM CET. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close99.44
Bid0.00 x 0
Ask0.00 x 0
Day's Range97.40 - 99.10
52 Week Range88.86 - 133.20
Avg. Volume126,282
Market Cap11.657B
Beta (5Y Monthly)-0.23
PE Ratio (TTM)23.04
EPS (TTM)4.28
Earnings DateMar 02, 2022
Forward Dividend & Yield0.62 (0.62%)
Ex-Dividend DateJun 04, 2021
1y Target Est130.96
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for BIM.PA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      French multidisciplinary consortium ARPEGE awarded public funding of close to €9 million to fight antibiotic resistance

      The ARPEGE[1] project aims to develop a set of solutions to strengthen the ability of healthcare institutions to fight antibiotic resistance. The consortium, led by Antabio, has been awarded close to €9 million in public funding under the "PSPC" call for projects conducted on behalf of the French government by Bpifrance.

    • Business Wire

      Baxter and bioMérieux Announce CE Mark for NEPHROCLEAR™ CCL14 Test to Predict Persistent Severe Acute Kidney Injury

      DEERFIELD, Ill. & MARCY L’ETOILE, France, October 21, 2021--Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux (EPA:BIM), a global leader in in vitro diagnostics, today announced the CE marking of the NEPHROCLEAR™ CCL14 Test. The NEPHROCLEAR™ CCL14 Test is designed to predict persistent severe acute kidney injury (PS-AKI) and can be used to support timely clinical decision-making and care pathways. The companies intend to commercially launch the NEPHROCLEAR™ CCL1


      bioMerieux to Exhibit at SupplySide West 2021 at Mandalay Bay in Las Vegas Oct. 25-28, 2021

      bioMérieux to Showcase its Full Suite of Nutraceutical Testing Solutions, Including the Recently Released GENE-UP® NUTRAPLEX PRO™ AssayCHICAGO, IL / ACCESSWIRE / October 5, 2021 / bioMérieux, a world leader in the field of in vitro diagnostics, will exhibit at SupplySide West 2021, the leading trade show for health and nutrition industry professionals focused on dietary supplements, beverages, functional foods, personal care, and sports nutrition innovation. SupplySide West 2021 will take place